Bivamelagon
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypothalamic Obesity
Conditions
Hypothalamic Obesity
Trial Timeline
Nov 10, 2025 → Apr 15, 2028
NCT ID
NCT07156578About Bivamelagon
Bivamelagon is a phase 2 stage product being developed by Rhythm Pharmaceuticals for Hypothalamic Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07156578. Target conditions include Hypothalamic Obesity.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07156578 | Phase 2 | Recruiting |
Competing Products
7 competing products in Hypothalamic Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Octreotide | Novartis | Approved | 85 |
| Mibavademab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718 | Rhythm Pharmaceuticals | Phase 1/2 | 38 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide | Rhythm Pharmaceuticals | Phase 2 | 49 |
| LB54640 + Placebo | Rhythm Pharmaceuticals | Phase 2 | 49 |